TY - JOUR T1 - One-third of European axial spondyloarthritis patients reach pain"remission" with routine care TNF-inhibitor treatment JF - The Journal of Rheumatology JO - J Rheumatol DO - 10.3899/jrheum.220459 SP - jrheum.220459 AU - Lykke Midtbøll Ørnbjerg AU - Kathrine Rugbjerg AU - Stylianos Georgiadis AU - Simon Horskjær AU - Lykke Midtbøll Ørnbjerg AU - Kathrine Rugbjerg AU - Stylianos Georgiadis AU - Simon Horskjær Rasmussen AU - Ulf Lindström AU - Karel Pavelka AU - Neslihan Yilmaz AU - Ennio Giulio Favalli AU - Michael J. Nissen AU - Brigitte Michelsen AU - Elsa Vieira-Sousa AU - Gareth T. Jones AU - Ruxandra Ionescu AU - Heikki Relas AU - Carlos Sanchez-Piedra AU - Matija Tomšič AU - Arni Jon Geirsson AU - Irene van der Horst-Bruinsma AU - Johan Askling AU - Anne Gitte Loft AU - Lucie Nekvindova AU - Haner Direskeneli AU - Florenzo Iannone AU - Karen Minde Fagerli AU - Maria José Santos AU - Gary J. Macfarlane AU - Catalin Codreanu AU - Kari Eklund AU - Manuel Pombo-Suarez AU - Ziga Rotar AU - Bjorn Gudbjornsson AU - Tamara Rusman AU - Mikkel Østergaard AU - Merete Lund Hetland Y1 - 2022/12/01 UR - http://www.jrheum.org/content/early/2022/11/25/jrheum.220459.abstract N2 - Objective To investigate the distribution of patient-reported outcomes (PROs) in axial spondyloarthritis (axSpA) patients initiating a tumor necrosis factor inhibitor (TNFi), to assess the proportion reaching PRO "remission" across registries and treatment series, and to compare patients registered to fulfill the New York criteria for ankylosing spondylitis (AS) versus non-radiographic axSpA (nr-axSpA) patients. Methods Fifteen European registries contributed PRO scores for pain, fatigue, patient global, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and Health Assessment Questionnaire (HAQ) from 19,498 axSpA patients. Changes in PROs and PRO "remission" rates (definitions: ≤20 mm for pain, fatigue, patient global, BASDAI and BASFI; ≤0.5 for HAQ) were calculated at 6, 12 and 24 months of treatment. Results Heterogeneity in baseline characteristics and outcomes between registries were observed. In pooled data, six months after start of a 1st TNFi, pain score was reduced by approximately 60% (median at baseline/6/12/24 months: 65/25/20/20 mm) in patients on treatment. Similar patterns were observed for fatigue (68/32/30/25), patient global (66/29/21/20), BASDAI (58/26/21/19), BASFI (46/20/16/16) and HAQ (0.8/0.4/0.2/0.2). Patients with AS, n=3281 had a slightly better response than nr-axSpA patients, n=993. LUNDEX-adjusted "remission" rates at 6 months for pain/fatigue/patient global/BASDAI/BASFI/HAQ were 39%/30%/38%/34%/35%/48% for the AS cohort and 30%/21%/26%/24%/33%/47% for the non-radiographic axSpA cohort. Better PRO responses were seen with a 1st TNFi compared to 2nd and 3rd TNFi. Conclusion AxSpA patients starting a TNFi achieved high PRO "remission" rates, most pronounced in those fulfilling the modified New York criteria and for the first TNFi. ER -